AI May Help With MRI Interpretation During Prostate Cancer Detection

Commentary
Video

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

CancerNetwork® spoke with Wayne G. Brisbane, MD during Prostate Cancer Awareness Month 2023 about how implementing artificial intelligence (AI) into the clinical landscape may help in detecting prostate cancer more effectively in patients who need to undergo an MRI.

Brisbane, an assistant professor of urology at the University of California, Los Angeles (UCLA) Health, discussed his experiences with a machine learning algorithm called Unfold AI in patients with elevated prostate specific antigen (PSA) levels who need to proceed to an MRI, which his practice often employs in prostate cancer detection. He described how the AI program may be able to elucidate signs of disease in an MRI that are not typically perceptible to the human eye, thereby giving information on how best to manage the tumor.

Transcript:

AI is being used in prostate cancer in a couple of different ways, mostly on the diagnostic side. I use it in men who come in with an elevated PSA, which is our best and most reliable way to screen men for prostate cancer. If you have an elevated PSA—I tell men it’s like a thermometer for your prostate; it goes up for all kinds of reasons—maybe it’s something in the prostate that could just be size or some inflammation, but it could be prostate cancer. [Therefore], we need to figure out exactly what that is for men.

We’re using AI to interpret the MRIs. After a PSA elevation, oftentimes men will get an MRI or a biomarker [assessment]—in my [practice], we use MRI quite a bit. We will use the MRIs, and if it doesn’t look like there’s anything to the naked eye, we’ll have an AI go and take a second look at it. [From there] if there is a lesion on the MRI and we do a biopsy. We’re using a machine learning algorithm called Unfold AI that carefully predicts the location and extent of the tumor. We use that to help us perform treatments.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content